drugset / Trial / NCT06974929

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

NCT06974929

Phase 1/2 Recruiting 80 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.

Timeline

Start
2025-05-22
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-2189 Unknown
Subject HRS-6209 Small molecule Oral
Background Letrozole Other / unclassified Oral

Indications